ReviewEuropean respiratory review : an official journal of the European Respiratory Society2011
Night-time symptoms: a forgotten dimension of COPD.
Review in European respiratory review : an official journal of the European Respiratory Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 5 syntheses or guidelines pooled it, 234 citations in OpenAlex.
- Differentiating the start of an exacerbation from day-to-day variation in people with COPD: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Therapeutic efficacy and pharmacological mechanism of Bailing capsule on chronic obstructive pulmonary disease: a meta-analysis and network pharmacology.Pharmaceutical biology · 2024Pooled it
- Daytime symptoms of chronic obstructive pulmonary disease: a systematic review.NPJ primary care respiratory medicine · 2020Pooled it
- Association between morning symptoms and physical activity in COPD: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2017Pooled it
- Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2015Pooled it
- Evening administration of long-acting muscarinic antagonists in COPD - a randomized controlled trial.BMC pulmonary medicine · 2025Trial
- Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.Respiratory research · 2020Trial
- Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.NPJ primary care respiratory medicine · 2017Trial
- Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.International journal of chronic obstructive pulmonary disease · 2017Trial
- Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).Respiratory research · 2015Trial
- Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2015Trial
- Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.Respiratory research · 2014Trial
- Trial
- Effect of background long-acting betaInternational journal of chronic obstructive pulmonary diseaseTrial
- A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.International journal of chronic obstructive pulmonary diseaseTrial
- Prevalence and impact of sleep disorders in patients with hereditary angioedema: A multicenter cross-sectional study in Latin America.Sleep & breathing = Schlaf & Atmung · 2026Article
- Cryptochrome Loss Drives COPD-like Lung Pathology through Disrupted Alveolar Epithelial Proliferation and Immune Homeostasis.bioRxiv : the preprint server for biology · 2026Article
- Effect of aclidinium bromide therapy on quality of life and symptoms of patients with chronic obstructive pulmonary disease: pooled analysis results of the Greek and Austrian ON-AIR real-world observational studies.BMC pulmonary medicine · 2026Observational
- Effect of evening vs. morning LAMA administration on risk of intensive care admission in COPD patients: influence of adherence post hoc analysis of the randomized controlled trial - LAMA BY NIGHT.European clinical respiratory journal · 2026Article
- Circadian clock regulation in lung health and disease: molecular mechanisms and therapeutic opportunities.EXCLI journal · 2026Review
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep quality is often poor in patients with chronic obstructive pulmonary disease (COPD), but these night-time symptoms are frequently unnoticed by physicians and/or not reported by patients themselves. Therefore, the prevalence and clinical impact of sleep disturbances and night-time symptoms in COPD is not well understood and has not been a clinical focus to date. To address this gap, an expert panel meeting was convened in Barcelona, Spain, in March 2011 to discuss the aetiology, evolution, burden, long-term clinical consequences and optimal management of night-time symptoms in COPD. The term "night-time symptoms" in COPD has not been distinctly defined in an objective sense but epidemiological data suggests that the prevalence of nocturnal symptoms and symptomatic sleep disturbance may exceed 75% in patients with COPD. The panel concluded that night-time symptoms in COPD are prevalent and bothersome; that their cause(s) are multiple and include demographic factors, such as age and obesity, pharmacotherapy, disease-specific symptoms and the presence of comorbid sleep disorders, and other medical conditions; and that potential long-term consequences can include lung function changes, increased exacerbation frequency, emergence or worsening of cardiovascular disease, cognitive effects, depression, impaired quality of life and increased mortality. To date, few interventional studies have investigated them, but emerging data suggest that bronchodilator therapy can improve them if deployed appropriately. In summary, night-time symptoms in COPD warrant further clinical investigation with validated tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.